140 related articles for article (PubMed ID: 3708600)
1. Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
Rascol A; Montastruc JL; Rascol O; Senard JM
Clin Neuropharmacol; 1986; 9(2):146-52. PubMed ID: 3708600
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled study of mesulergine in Parkinson's disease.
Jankovic J; Orman J; Jansson B
Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
[TBL] [Abstract][Full Text] [Related]
3. Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.
Schneider E; Baas H; Fischer PA; Japp G
J Neurol; 1985; 232(1):24-8. PubMed ID: 3998771
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pergolide and mesulergine.
Lieberman AN; Gopinathan G; Neophytides A
Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
[TBL] [Abstract][Full Text] [Related]
5. Mesulergine in early Parkinson's disease: a double blind controlled trial.
Dupont E; Mikkelsen B; Jakobsen J
J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):390-5. PubMed ID: 3517235
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
Schneider E; Hubener K; Fischer PA
Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
[TBL] [Abstract][Full Text] [Related]
7. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
8. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
Pfeiffer RF; Wilken K; Glaeske C
Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
[TBL] [Abstract][Full Text] [Related]
9. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
[TBL] [Abstract][Full Text] [Related]
10. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
[TBL] [Abstract][Full Text] [Related]
11. CQA 206-291 in Parkinson's disease: an acute single escalating dosage study.
Lang AE; Riley DE; Vachon L; Lataste X
Can J Neurol Sci; 1990 Nov; 17(4):416-9. PubMed ID: 2276100
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
Ahlskog JE; Wright KF; Muenter MD; Adler CH
Clin Neuropharmacol; 1996 Jun; 19(3):202-12. PubMed ID: 8726539
[TBL] [Abstract][Full Text] [Related]
13. Mesulergine: a dopamine agonist with novel properties in Parkinson's disease.
Lieberman AN; Gopinathan G; Pasternack P; Goldstein M
Adv Neurol; 1990; 53():533-7. PubMed ID: 1978521
[No Abstract] [Full Text] [Related]
14. Mesulergine and pergolide in previously untreated Parkinson's disease.
Wright A; Lees AJ; Stern GM
J Neurol Neurosurg Psychiatry; 1987 Apr; 50(4):482-4. PubMed ID: 3585362
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Marsden CD
Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
Jellinger K
J Neurol; 1982; 227(2):75-88. PubMed ID: 6180142
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of pergolide in Parkinson's disease].
Gonce M; Delwaide PJ
Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease: a comparison of mesulergine and bromocriptine.
Burton K; Larsen TA; Robinson RG; Bratty PJ; Martin WR; Schulzer M; Calne DB
Neurology; 1985 Aug; 35(8):1205-8. PubMed ID: 3895033
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
Biesemeyer H; Ludin HP; Ringwald E
J Neurol; 1983; 230(1):19-23. PubMed ID: 6194269
[TBL] [Abstract][Full Text] [Related]
20. Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.
Baas H; Schneider E; Fischer PA; Japp G
J Neural Transm; 1985; 64(1):45-54. PubMed ID: 4067602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]